Processing

Please wait...

Settings

Settings

Goto Application

1. WO1999007394 - USE OF HERPES VECTORS FOR TUMOR THERAPY

Publication Number WO/1999/007394
Publication Date 18.02.1999
International Application No. PCT/US1998/016447
International Filing Date 12.08.1998
Chapter 2 Demand Filed 12.03.1999
IPC
A61K 35/76 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
A61K 38/19 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
A61K 38/20 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins
A61K 48/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
CPC
A01K 2267/0331
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
2267Animals characterised by purpose
03Animal model, e.g. for test or diseases
0331Animal model for proliferative diseases
A61K 35/763
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
763Herpes virus
A61K 38/1774
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
177Receptors; Cell surface antigens; Cell surface determinants
1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
A61K 38/193
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
193Colony stimulating factors [CSF]
A61K 38/208
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins [IL]
208IL-12
A61K 39/245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
245Herpetoviridae, e.g. herpes simplex virus
Applicants
  • GEORGETOWN UNIVERSITY [US]/[US] (AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BY, CA, CF, CG, CH, CI, CM, CN, CU, CY, CZ, DE, DK, EE, ES, FI, FR, GA, GB, GE, GH, GM, GN, GR, GW, HR, HU, ID, IE, IL, IS, IT, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MC, MD, MG, MK, ML, MN, MR, MW, MX, NE, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SN, SZ, TD, TG, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW)
  • RABKIN, Samuel, D. [CA]/[US] (UsOnly)
  • TODA, Masahiro [JP]/[JP] (UsOnly)
  • MARTUZA, Robert, L. [US]/[US] (UsOnly)
Inventors
  • RABKIN, Samuel, D.
  • TODA, Masahiro
  • MARTUZA, Robert, L.
Agents
  • BENT, Stephen, A.
Priority Data
09/064,17422.04.1998US
60/055,14212.08.1997US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) USE OF HERPES VECTORS FOR TUMOR THERAPY
(FR) UTILISATION DE VECTEURS D'HERPES POUR LE TRAITEMENT DE TUMEURS
Abstract
(EN) Eliciting a systemic antitumor immune response, in a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type, entails, in one embodiment, inoculating a tumor in the patient with a pharmaceutical composition consisting essentially of (A) a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells and (B) a pharmaceutically acceptable vehicle for the virus, such that an immune response is induced that is specific for the tumor cell type and that kills cells of the inoculated tumor and of a non-inoculated tumor. In another embodiment, the pharmaceutical composition also comprises a defective HSV vector which contains an expressible nucleotide sequence encoding at least one immune modulator. In another embodiment, the pharmaceutical composition contains a second HSV that infects tumor cells but that does not spread in normal cells. According to the latter approach, both the first HSV and the second HSV may have genomes that comprise, respectively, an expressible nucleotide sequence coding for at least one immune modulator. In another embodiment, the pharmaceutical composition comprises, in addition to a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells, a viral vector comprising at least one expressible nucleotide sequence coding for at least one immune modulator.
(FR) L'invention concerne des méthodes permettant de solliciter une réponse immunitaire anti-tumorale systémique chez un patient présentant ou risquant de développer des métastases multiples d'un type cellulaire donné. Un des modes d'application consiste à inoculer la tumeur du patient avec une composition pharmaceutique comprenant essentiellement (A) un virus herpès simplex (HSV) qui infecte les cellules tumorales mais ne se propage pas aux cellules normales et (B) un véhicule pharmaceutiquement acceptable pour le virus, afin d'induire une réponse immunitaire qui est spécifique au type cellulaire de la tumeur et qui provoque la destruction les cellules de la tumeur (Rt) et d'une tumeur non-inoculée (Lt). Dans un autre mode de réalisation la composition pharmaceutique comprend en outre un vecteur HSV défectueux qui contient une séquence nucléotidique pouvant être exprimée, codant au moins un immunomodulateur. Dans un autre mode de réalisation, la composition pharmaceutique contient un second HSV qui infecte les cellules tumorales mais ne se propage pas aux cellules normales. Dans cette dernière approche, le premier HSV et le second HSV peuvent comprendre des génomes qui comprennent respectivement une séquence nucléotidique exprimable codant au moins pour un immunomodulateur. Dans un autre mode de réalisation, la composition phamaceutique comprend, outre le virus herpès simplex (HSV) qui infecte les cellules tumorale mais ne se propage pas aux cellules normales, un vecteur viral comprenant au moins un séquence nucléotidique pouvant être exprimée, codant pour au moins un immunomodulateur.
Latest bibliographic data on file with the International Bureau